EUVIMEDEUVIMED entdecken
Crossref

Real-World Use of AKI Biomarkers: A Quality Improvement Project Using Urinary Tissue Inhibitor Metalloprotease-2 and Insulin-Like Growth Factor Binding Protein 7 ([TIMP-2]*[IGFBP7])

Ashley M La, Samantha Gunning, Sharon A Trevino, Alissa Kunczt, Lui G Forni, Varsha Swamy, Alexander Zarbock, Sarah Groboske, Edward K Y Leung, Kiang-Teck J Yeo, Jay L Koyner

American Journal of Nephrology · 2023

DOI: 10.1159/000531641 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Nephrology, 2023. Verfasst von Ashley M La und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Chicago, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Tissue Inhibitor of Metalloproteinase-2, Acute Kidney Injury. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Novel urinary biomarkers, including tissue inhibitor metalloprotease-2 and insulin-like growth factor binding protein 7 ([TIMP-2]*[IGFBP7]), have been developed to identify patients at risk for acute kidney injury (AKI). We investigated the “real-world” clinical utility of [TIMP-2]*[IGFBP7] in preventing AKI.

Methods

We performed a before and after single-center quality improvement study of intensive care unit (ICU) patients at risk for severe (KDIGO stage 2 or 3) AKI. In the prospective cohort, ICU providers were allowed to order [TIMP-2]*[IGFBP7] for patients at their discretion, then offered AKI practice recommendations based on the results. Outcomes were compared to a historical cohort in which biomarker values were not reported to clinical teams.

Results

There was no difference in 7-day progression to severe AKI between the prospective (n = 116) and historical cohorts (n = 63) when [TIMP-2]*[IGFBP7] ≥0.3 (24 [28%] versus 8 [21%], p = 0.38) despite more stage 1 AKI at time of biomarker measurement in the prospective cohort (58 [67%] versus 9 [23%], p < 0.001). In the prospective cohort, patients with higher [TIMP-2]*[IGFBP7] values were more likely to receive a nephrology consult. Early consultation (within 24 h of biomarker measurement, n = 20) had a nonsignificant trend toward net negative volume balance (−1,787 mL [6,716 mL] versus + 4,974 mL [15,540 mL]) and more diuretic use (19 [95%] versus 8 [80%]) and was associated with less severe AKI (9 [45%] versus 10 [100%], p = 0.004) and inpatient dialysis (2 [10%] versus 7 [70%], p = 0.002) compared to delayed consultation (n = 10).

Conclusions

Despite the prospective cohort having more preexisting stage 1 AKI, there were equal rates of progression to severe AKI in the prospective and historical cohorts. In the setting of [TIMP-2]*[IGFBP7] reporting, there were more nephrology consults in response to elevated biomarker levels. Early nephrology consultation resulted in improved volume balance and favorable outcomes compared to delayed consultation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tissue Inhibitor of Metalloproteinase-2Acute Kidney InjuryHumansProspective StudiesQuality ImprovementBiomarkersInsulin-Like Growth Factor Binding Proteins

Stichwörter der Autor:innen

Acute kidney injuryBiomarkersMortalityNephrology consultQuality initiativeRenal replacement therapy

Substanzen

Tissue Inhibitor of Metalloproteinase-2BiomarkersInsulin-Like Growth Factor Binding Proteins

Autor:innen und Institutionen

  • Department of Internal Medicine, University of Chicago, Chicago, Illinois, USA.
  • Section of Nephrology, Department of Internal Medicine, University of Chicago, Chicago, Illinois, USA.
  • Department of Intensive Care Medicine, Royal Surrey Hospital and Faculty of Health Sciences, University of Surrey, Guildford, UK.
  • Department of Anesthesiology, Intensive Care Medicine and Pain Medicine, University Hospital Munster, Munster, Germany.
  • Outcomes Research Consortium, Cleveland, Ohio, USA.
  • Section of Clinical Chemistry, Department of Pathology, University of Chicago, Chicago, Illinois, USA.

Zitieren

APA

La, A. M., Gunning, S., Trevino, S. A., Kunczt, A., Forni, L. G., Swamy, V., Zarbock, A., Groboske, S., Leung, E. K. Y., Yeo, K. J., & Koyner, J. L. (2023). Real-World Use of AKI Biomarkers: A Quality Improvement Project Using Urinary Tissue Inhibitor Metalloprotease-2 and Insulin-Like Growth Factor Binding Protein 7 ([TIMP-2]*[IGFBP7]). American Journal of Nephrology. https://doi.org/10.1159/000531641

Vancouver

La AM, Gunning S, Trevino SA, Kunczt A, Forni LG, Swamy V, et al. Real-World Use of AKI Biomarkers: A Quality Improvement Project Using Urinary Tissue Inhibitor Metalloprotease-2 and Insulin-Like Growth Factor Binding Protein 7 ([TIMP-2]*[IGFBP7]). American Journal of Nephrology. 2023. doi:10.1159/000531641

BibTeX
@article{La2023,
  author = {La, Ashley M and Gunning, Samantha and Trevino, Sharon A and Kunczt, Alissa and Forni, Lui G and Swamy, Varsha and Zarbock, Alexander and Groboske, Sarah and Leung, Edward K Y and Yeo, Kiang-Teck J and Koyner, Jay L},
  title = {Real-World Use of AKI Biomarkers: A Quality Improvement Project Using Urinary Tissue Inhibitor Metalloprotease-2 and Insulin-Like Growth Factor Binding Protein 7 ([TIMP-2]*[IGFBP7])},
  journal = {American Journal of Nephrology},
  year = {2023},
  doi = {10.1159/000531641}
}
Kostenlos starten →